Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

99.70 0.29 −0.29%
Market cap
$6.5B
P/E
23.7×
Fwd P/E
25.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
14.59% 21.45% 23.48% 22.21%
ROA
7.75% 11.10% 12.68% 12.15%
ROIC
16.63% 14.94% 14.12% 14.65%
Return on Tangible Assets
22.59% 31.98% 36.39% 32.59%
Average Days of Receivables
91.67 88.56 84.31 83.04
Free Cash Flow per Share
6.30 5.25 5.90 6.03
Free Cash Flow
423.79 354.05 382.11 392.83
Other line items

Show all line items

Columns are period end dates